Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Ophthalmology

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    April 2021
    A Holistic Perspective in Caring for People with Diabetic Retinopathy.
    Ophthalmology. 2021;128:574-575.

    March 2021
  2. MALHOTRA NA, Greenlee TE, Iyer AI, Conti TF, et al
    Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti-VEGF Therapy for Diabetic Macular Edema in the United States.
    Ophthalmology. 2021 Mar 11. pii: S0161-6420(21)00196.
    PubMed     Abstract available

    February 2021
  3. CUI Y, Zhu Y, Lu ES, Le R, et al
    Widefield Swept-source OCT Angiography Metrics Associated with the Development of Diabetic Vitreous Hemorrhage A Prospective Study.
    Ophthalmology. 2021 Feb 26. pii: S0161-6420(21)00154.
    PubMed     Abstract available

    December 2020
  4. MODJTAHEDI BS, Wu J, Luong TQ, Gandhi NK, et al
    Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality.
    Ophthalmology. 2020 Dec 24. pii: S0161-6420(20)31195.
    PubMed     Abstract available

    November 2020
  5. SUN JK, Aiello LP, Abramoff MD, Antonetti DA, et al
    Updating the Staging System for Diabetic Retinal Disease.
    Ophthalmology. 2020 Nov 17. pii: S0161-6420(20)31005.

    October 2020
  6. LOIS N, Cook JA, Wang A, Aldington S, et al
    Evaluation of a new model of care for people with complications of diabetic retinopathy: The EMERALD Study.
    Ophthalmology. 2020 Oct 29. pii: S0161-6420(20)31032.
    PubMed     Abstract available

    September 2020
  7. HAINSWORTH DP, Gao X, Bebu I, Das A, et al
    Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: the DCCT/EDIC Study.
    Ophthalmology. 2020 Sep 14. pii: S0161-6420(20)30896.
    PubMed     Abstract available

    July 2020
  8. CHEN EM, Chen D, Chilakamarri P, Lopez R, et al
    Economic Challenges of Artificial Intelligence Adoption for Diabetic Retinopathy.
    Ophthalmology. 2020 Jul 24. pii: S0161-6420(20)30733.
    PubMed     Abstract available

  9. CHAUM E
    Detection of Lipemia Retinalis During Telemedical Diabetic Retinopathy Screening.
    Ophthalmology. 2020;127:900.

    Expanding Coverage Does Not Guarantee a Benefit.
    Ophthalmology. 2020;127:929-930.

    May 2020
  11. WINTERGERST MWM, Mishra DK, Hartmann L, Shah P, et al
    Diabetic retinopathy screening using smartphone-based fundus imaging in India.
    Ophthalmology. 2020 May 14. pii: S0161-6420(20)30463.
    PubMed     Abstract available

  12. BORRELLI E, Sacconi R, Querques G
    Re: Couturier et al.: Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor (Ophthalmology. 2019;126:1685-1694).
    Ophthalmology. 2020;127:e32-e34.

  13. COUTURIER A, Lavia C, Gaudric A, Tadayoni R, et al
    Ophthalmology. 2020;127:e34-e35.

    April 2020

  14. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs - An Extension of the Modified Airlie House Classification: ETDRS Report Number 10.
    Ophthalmology. 2020;127.
    PubMed     Abstract available

  15. SADDA SR
    Assessing the Severity of Diabetic Retinopathy: Early Treatment Diabetic Retinopathy Study Report Number 10.
    Ophthalmology. 2020;127.

  16. MAA AY, McCord S, Lu X, Janjua R, et al
    The Impact of OCT on Diagnostic Accuracy of the Technology-Based Eye Care Services Protocol: Part II of the Technology-Based Eye Care Services Compare Trial.
    Ophthalmology. 2020;127:544-549.
    PubMed     Abstract available

  17. BRANDT JD, Beiser JA, Kass MA, Gordon MO, et al
    Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS).
    Ophthalmology. 2020;127.
    PubMed     Abstract available

    March 2020
  18. GLASSMAN AR, Wells JA 3rd, Josic K, Maguire MG, et al
    Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Ophthalmology. 2020 Mar 29. pii: S0161-6420(20)30304.
    PubMed     Abstract available

    December 2019
  19. TSUBOI K, Ishida Y, Kamei M
    Congenital Retinal Macrovessel Strays into Deep Capillary Plexus.
    Ophthalmology. 2019;126:1658.

    November 2019
  20. BHANDARI S, Nguyen V, Fraser-Bell S, Mehta H, et al
    Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
    Ophthalmology. 2019 Nov 26. pii: S0161-6420(19)32299.
    PubMed     Abstract available

    October 2019
  21. CANTRELL RA, Lum F, Chia Y, Morse LS, et al
    Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS(R)) Registry Analysis.
    Ophthalmology. 2019 Oct 23. pii: S0161-6420(19)32176.

  22. ROSENBLATT A, Udaondo P, Cunha-Vaz J, Sivaprasad S, et al
    A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.
    Ophthalmology. 2019 Oct 10. pii: S0161-6420(19)32112.
    PubMed     Abstract available

    September 2019
  23. FLAXEL CJ, Adelman RA, Bailey ST, Fawzi A, et al
    Diabetic Retinopathy Preferred Practice Pattern(R).
    Ophthalmology. 2019 Sep 25. pii: S0161-6420(19)32092.

  24. CHEN EM, Armstrong GW, Cox JT, Wu DM, et al
    Association of the Affordable Care Act Medicaid Expansion with Dilated Eye Examinations among the United States Population with Diabetes.
    Ophthalmology. 2019 Sep 17. pii: S0161-6420(19)32056.
    PubMed     Abstract available

  25. JUNCAL VR, Paracha Q, Bamakrid M, Francisconi CLM, et al
    Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection.
    Ophthalmology. 2019 Sep 12. pii: S0161-6420(19)31953.

  26. MANDVIWALA MM, Weinberg DV, Hwang ES
    Edema within Epiretinal Proliferation in a Diabetic Patient.
    Ophthalmology. 2019;126:1272.

    August 2019
  27. GONZALEZ VH, Wang PW, Ruiz CQ
    Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
    Ophthalmology. 2019 Aug 21. pii: S0161-6420(19)31932.
    PubMed     Abstract available

    June 2019
  28. SUN Z, Tang F, Wong R, Lok J, et al
    OCT Angiography Metrics Predict Progression of Diabetic Retinopathy and Development of Diabetic Macular Edema: A Prospective Study.
    Ophthalmology. 2019 Jun 26. pii: S0161-6420(19)30608.
    PubMed     Abstract available

  29. COUTURIER A, Rey PA, Erginay A, Lavia C, et al
    Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
    Ophthalmology. 2019 Jun 26. pii: S0161-6420(19)30304.
    PubMed     Abstract available

  30. EPPLEY SE, Mansberger SL, Ramanathan S, Lowry EA, et al
    Characteristics Associated with Adherence to Annual Dilated Eye Examinations among US Patients with Diagnosed Diabetes.
    Ophthalmology. 2019 Jun 15. pii: S0161-6420(19)30130.
    PubMed     Abstract available

  31. EHLERS JP, Jiang AC, Boss JD, Hu M, et al
    Quantitative Ultra-Widefield Angiography and Diabetic Retinopathy Severity: An Assessment of Panretinal Leakage Index, Ischemic Index and Microaneurysm Count.
    Ophthalmology. 2019 Jun 8. pii: S0161-6420(19)30413.
    PubMed     Abstract available

    May 2019
  32. FRANK RN
    Anti-Vascular Endothelial Growth Factor Injections for Diabetic Retinopathy: Continued Progress, More Questions.
    Ophthalmology. 2019;126:721-722.

    April 2019
  33. WYKOFF CC, Shah C, Dhoot D, Coleman HR, et al
    Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA study.
    Ophthalmology. 2019 Apr 1. pii: S0161-6420(18)33320.
    PubMed     Abstract available

    Ciliary Neurotrophic Factor Treatment Improves Retinal Structure and Function in Macular Telangiectasia Type 2.
    Ophthalmology. 2019;126:550-551.

    March 2019
  35. SAHNI J, Patel SS, Dugel PU, Khanani AM, et al
    Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Ophthalmology. 2019 Mar 21. pii: S0161-6420(18)33358.
    PubMed     Abstract available

    If There Is Loss to Follow Up, Poor Outcomes May Be More Common after Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Retinopathy.
    Ophthalmology. 2019;126:414.

    November 2018
  37. SAYRES R, Taly A, Rahimy E, Blumer K, et al
    Using a deep learning algorithm and integrated gradients explanation to assist grading for diabetic retinopathy.
    Ophthalmology. 2018 Nov 28. pii: S0161-6420(18)31575.
    PubMed     Abstract available

  38. SUN JK, Wang PW, Taylor S, Haskova Z, et al
    Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies.
    Ophthalmology. 2018 Nov 9. pii: S0161-6420(18)30817.
    PubMed     Abstract available

  39. DU S, Chen S
    Re: Jampol et al.: Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema (Ophthalmology. 2018;7:1054-1063).
    Ophthalmology. 2018;125:e81-e82.

    October 2018
  40. MALONEY MH, Schilz SR, Herrin J, Sangaralingham LR, et al
    Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
    Ophthalmology. 2018 Oct 4. pii: S0161-6420(18)30063.
    PubMed     Abstract available

    September 2018
  41. SRIVASTAV K, Baskaran P
    Re: Zur et al.: OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant (Ophthalmology. 2018;125:267-275).
    Ophthalmology. 2018;125:e61.

    August 2018
  42. NAKASHIMA H, Iwama Y, Tanioka K, Emi K, et al
    Paracentral Acute Middle Maculopathy following Vitrectomy for Proliferative Diabetic Retinopathy: Incidence, Risk Factors, and Clinical Characteristics.
    Ophthalmology. 2018 Aug 17. pii: S0161-6420(18)30905.
    PubMed     Abstract available

  43. SUN JK, Glassman AR, Beaulieu WT, Stockdale CR, et al
    Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Aug 7. pii: S0161-6420(18)31489.
    PubMed     Abstract available

  44. OBEID A, Su D, Patel SN, Uhr JH, et al
    Outcomes of Eyes Lost to Follow-Up with Proliferative Diabetic Retinopathy that received Panretinal Photocoagulation vs Intravitreal Anti-Vascular Endothelial Growth Factor.
    Ophthalmology. 2018 Aug 2. pii: S0161-6420(18)31079.
    PubMed     Abstract available

    July 2018
  45. BRESSLER SB, Beaulieu WT, Glassman AR, Gross JG, et al
    Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Ophthalmology. 2018 Jul 3. pii: S0161-6420(18)30577.
    PubMed     Abstract available

    May 2018
  46. KLEIN R, Lee KE, Danforth L, Tsai MY, et al
    The Relationship of Retinal Vessel Geometric Characteristics to the Incidence and Progression of Diabetic Retinopathy.
    Ophthalmology. 2018 May 17. pii: S0161-6420(18)30530.
    PubMed     Abstract available

  47. WONG TY, Sun J, Kawasaki R, Ruamviboonsuk P, et al
    Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.
    Ophthalmology. 2018 May 15. pii: S0161-6420(17)33523.
    PubMed     Abstract available

  48. REDDY RK, Pieramici DJ, Gune S, Ghanekar A, et al
    Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Ophthalmology. 2018 May 8. pii: S0161-6420(17)33607.
    PubMed     Abstract available

  49. PAYNE JF, Clark WL, Bruce BB, Wykoff CC, et al
    Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
    Ophthalmology. 2018 May 2. pii: S0161-6420(18)30678.

    March 2018
  50. LIN J, Chang JS, Yannuzzi NA, Smiddy WE, et al
    Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(18)30040.
    PubMed     Abstract available

  51. OBEID A, Gao X, Ali FS, Talcott KE, et al
    Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(17)33569.
    PubMed     Abstract available

  52. YANNUZZI NA, Sridhar J, Chang JS, Lin J, et al
    Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(18)30299.

  53. GUPTA P, Liang Gan AT, Kidd Man RE, Fenwick EK, et al
    Impact of Incidence and Progression of Diabetic Retinopathy on Vision-Specific Functioning.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(17)32967.
    PubMed     Abstract available

  54. JAMPOL LM, Glassman AR, Liu D, Aiello LP, et al
    Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Ophthalmology. 2018 Mar 7. pii: S0161-6420(17)32232.
    PubMed     Abstract available

  55. KRAUSE J, Gulshan V, Rahimy E, Karth P, et al
    Grader Variability and the Importance of Reference Standards for Evaluating Machine Learning Models for Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 2. pii: S0161-6420(17)32698.
    PubMed     Abstract available

    February 2018
  56. LIU L, Tham YC
    Re: Keel et al.: The prevalence of diabetic retinopathy in Australian adults with self-reported diabetes: The National Eye Health Survey (Ophthalmology. 2017;124:977-984).
    Ophthalmology. 2018;125:e13-e14.

    January 2018
  57. FIGUEIRA J, Fletcher E, Massin P, Silva R, et al
    Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Ophthalmology. 2018 Jan 27. pii: S0161-6420(17)32188.
    PubMed     Abstract available

  58. BROWN DM, Ou WC, Wong TP, Kim RY, et al
    Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Ophthalmology. 2018 Jan 11. pii: S0161-6420(17)31641.
    PubMed     Abstract available

  59. GRZYBOWSKI A, Kanclerz P
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e8-e9.

  60. JONNA G, Kim SJ
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e4.

    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e10-e11.

    December 2017
  62. TAN GS, Gan A, Sabanayagam C, Tham YC, et al
    Ethnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy: The Singapore Epidemiology of Eye Diseases Study.
    Ophthalmology. 2017 Dec 4. pii: S0161-6420(17)31893.
    PubMed     Abstract available

  63. THOMAS M, Rao RC, Johnson MW, Paulus YM, et al
    Re: Bressler et al.: Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab (Ophthalmology. 2017;124:431-439).
    Ophthalmology. 2017;124:e87-e88.

    September 2017
  64. ZUR D, Iglicki M, Busch C, Invernizzi A, et al
    Optical Coherence Tomography Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.
    Ophthalmology. 2017 Sep 18. pii: S0161-6420(17)32014.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.